PAMELA HAMILTON: Open Payments
NPI 1639147846 · DALLAS, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,620 in 123 payments from 21 companies in 2025. Trend: 2023 $2,333 · 2024 $2,018 · 2025 $2,620
Food & beverage: $2,541Education: $80
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 30 | $409 |
| Alkermes, Inc. | 10 | $273 |
| Corium, LLC | 10 | $261 |
| Teva Pharmaceuticals USA, Inc. | 7 | $241 |
| Axsome Therapeutics, Inc. | 8 | $241 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 9 | $220 |
| Otsuka America Pharmaceutical, Inc. | 12 | $165 |
| Supernus Pharmaceuticals, Inc. | 8 | $159 |
| Lundbeck LLC | 5 | $129 |
| Neurocrine BioSciences, Inc. | 3 | $98 |
Products named: VRAYLAR, REXULTI, Azstarys, Auvelity, CAPLYTA, ARISTADA, AUSTEDO XR, Qelbree.
Industry payments across TX — which companies pay providers there.
